Leerink lowered the firm’s price target on CorMedix (CRMD) to $13 from $15 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- Buy Rating Maintained as Long-Term Rezzayo Upside Remains Underappreciated Despite Near-Term Weakness
- CorMedix reports Q4 EPS 16c vs 20c last year
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Low P/E Alert! These 3 Undervalued Stocks Are Poised to Surge Over 90%
- Cormedix: Rezzayo and DefenCath Prophylaxis Upside Underscores Buy Rating and $13 DCF-Based Target